SCHEMBL7632015

SCHEMBL7632015

NCCC(C(=O)O)n1c(=O)cc[nH]c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 1/20 0.36
GRM4 Q14833 1/20 0.36
POLB P06746 5/20 0.34
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 3/20 0.32
HSD17B10 Q99714 2/20 0.32
TP53 P04637 1/20 0.32
GLA P06280 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
HPGD P15428 1/20 0.32
ALOX12 P18054 1/20 0.32
NFKB1 P19838 1/20 0.32
APEX1 P27695 1/20 0.32
MAPK1 P28482 1/20 0.32
GABRR1 P24046 2/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CPB2 Q96IY4 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5290084 0.75 ALDH1A1 (0.38) GRM8GRM4POLBMAPTALDH1A1
SCHEMBL725456 0.73 ALDH1A1 (0.41) GRM8GRM4POLBMAPTALDH1A1
SCHEMBL27628887 0.71 MAPT (0.38) POLBMAPTALDH1A1KDM4EHSD17B10
SCHEMBL5479286 0.70 ALDH1A1 (0.38) POLBMAPTALDH1A1
SCHEMBL301397 0.70 ALDH1A1 (0.35) POLBMAPTALDH1A1KDM4EMEN1
SCHEMBL154274 0.69 GRM5 (0.47) GRM8GRM4GRIA1GRIA2GRIA3
SCHEMBL107537 0.69 GRIA1 (0.35) GRIA1GRIA2GRIA3GRIA4GRIK5
SCHEMBL5282402 0.68 GRIA1 (0.51) MAPTALDH1A1KDM4ECYP3A4NFKB1
SCHEMBL2930015 0.67 HASPIN (0.35) KMT2ATDP1L3MBTL1
SCHEMBL2930014 0.67 BRD4 (0.32) POLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725474-B2 Modified nucleic acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-08 US claimed
EP-2915815-B1 NEW MODIFIED NUCLEIC ACID TAKEDA PHARMACEUTICALS CO (JP) 2018-01-17 EP disclosed
US-9725474-B2 Modified nucleic acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-08 US disclosed
US-20160016983-A1 New Modified Nucleic Acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-21 US disclosed
EP-2915815-A1 NEW MODIFIED NUCLEIC ACID Takeda Pharmaceutical Company Limited (JP) 2015-09-09 EP disclosed
US-20020137135-A1 Novel NPG-1 gene that is differentially expressed in prostate tumors BETH ISRAEL DEACONESS MEDICAL CENTER, INC., A MASSACHUSETTS CORPORATION 2002-09-26 US disclosed
US-6287777-B1 SEVERAL GENES EXPRESSED DIFFERENTIALLY BETWEEN THE HUMAN PROSTATE CARCINOMA CELL LINES LNCAP AND PC-3, WHICH ARE ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT, RESPECTIVELY, HAVE NOW BEEN ISOLATED. ONE OF THESE GENES, DESIGNATED NPG-1. BETH ISRAEL DEACONESS MEDICAL CENTER 2001-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016983-A1 New Modified Nucleic Acid RNGTT, RNASEH1, RNASE1 GRM8 2644/4885GRM4 3603/4885POLB 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.